Losing CD45 and various B-cell markers in a case of MYC-driven pediatric high-grade B-cell lymphoma, not otherwise specified that transformed from Burkitt’s lymphoma during rituximab-containing treatments: a case report
暂无分享，去创建一个
T. Qiu | X. Xue | Xiaojun Wang | Lejian He | L. Fu | Z. Cao | W. Rao | Yiyang Luo | Xiaoli Feng
[1] S. Turner,et al. Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma , 2021, Leukemia.
[2] R. Sachdev,et al. CD45-negative primary diffuse large B-cell lymphoma of the cerebellum. , 2015, Neurology India.
[3] Ana Marta Pires,et al. Flow cytometry CD45‐negative B‐NHL: A case report of a diffuse large B‐cell lymphoma without extranodal involvement , 2012, Cytometry. Part B, Clinical cytometry.
[4] K. Fukuchi,et al. CD20 gene deletion causes a CD20‐negative relapse in diffuse large B‐cell lymphoma , 2012, European journal of haematology.
[5] R. Spang,et al. Deep Sequencing of MYC DNA-Binding Sites in Burkitt Lymphoma , 2011, PloS one.
[6] K. Becker,et al. Time-Dependent c-Myc Transactomes Mapped by Array-Based Nuclear Run-On Reveal Transcriptional Modules in Human B Cells , 2010, PloS one.
[7] G. Nuovo,et al. The absence of CD20 messenger RNA in recurrent cutaneous B‐cell lymphoma following rituximab therapy , 2005, Journal of cutaneous pathology.